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Because cancers are caused by deregulation of hundreds of genes, an ideal anticancer agent should target multiple gene products
or signaling pathways simultaneously. Recently, extensive research has addressed the chemotherapeutic potential of plant-derived
compounds. Among the ever-increasing list of naturally occurring anticancer agents, Rottlerin appears to have great potentiality
for being used in chemotherapy because it aﬀects several cell machineries involved in survival, apoptosis, autophagy, and invasion.
The underlying mechanisms that have been described are diverse, and the ﬁnal, cell-speciﬁc, Rottlerin outcome appears to result
from a combination of signaling pathways at multiple levels. This paper seeks to summarize the multifocal signal modulatory pro-
perties of Rottlerin, which merit to be further exploited for successful prevention and treatment of cancer.
1.Introduction
Drug discovery from medicinal plants has played an impor-
tant role in the treatment of cancer, and, indeed, a large maj-
ority of available anticancer drugs are natural products or
natural product-derived drugs, or natural product mimics
[1]. Emblematic examples of plant-derived compounds that
enteredin(phaseI–III)clinicaltrialsincludecurcumin,geni-
stein, soy isoﬂavones, green tea/epigallocatechin gallate, and
resveratrol [2]. These and other promising phytochemical
agents,belonging todiverse structuraland functionalchemi-
cal classes, work by various mechanisms of action to prevent,
arrest, or reverse either the initiation phase or the progres-
sion of carcinogenesis.
Because cancers are caused by deregulation of hundreds
of genes [3], an ideal anticancer agent should target simulta-
neously multiple gene products or signaling pathways.
Most of the plant-derived agents, which have been also
studied by a mechanistic point of view, are signal transduc-
tionmodulators,hormonemodulators,anti-inﬂammatories,
antimutagens, and antioxidants.
This review intends to present the multiple pharmaco-
logical properties of Rottlerin, an old/new natural substance
that, over the years, has revealed a bewildering number of
cellular and molecular targets, all potentially implicated in
the control of (cancer) cell life and death.
2. The Source of Rottlerin
The Mallotus Philippinensis, also known as Kamala Tree
(Figure 1),growsinthetropicalregionsofIndia,Philippines,
Southeast Asia, and Australia. This rain forest, evergreen tree
produces a fruit that, when ripe (February and March), is
covered with a red powder, which is collected by simply
rolling theberries. This powder, calledkamala, is used locally
to produce an orange-brown die for coloring textiles and,
suspended in water, mucilage or syrup, is also used as an old
folk remedy against tape-worm, because of its laxative eﬀect
[4]. Though no scientiﬁc records exist, other folkloric uses
include various aﬄictions of the skin, particularly scabies
and herpetic ringworm, in which Kamala is used as a topical
remedy. The powder is also used in treating eye diseases,
bronchitis, abdominal disease, spleen enlargement and other
illnesses, and legend says it is a powerful aphrodisiac [5].
In more recent history, phloroglucinol derivatives ex-
tracted from various parts of the Kamala tree have been
demonstratedtohaveantifertilityactions[6]andantiallergic
properties [7].2 The Scientiﬁc World Journal
Figure 1: The Kamala tree.
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Figure 2: The Rottlerin structure.
Rottlerin, also called mallotoxin (Figure 2), is the prin-
cipal phloroglucinol constituent of kamala and can be ex-
tracted, puriﬁed, and concentrated from the powder [8]. The
IUPAC name for Rottlerin is (E)-1-[6-[(3-acetyl-2,4,6-tri-
hydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-di-
methylchromen-8-yl]-3-phenylprop-2-en-1-one. The mole-
cularformulaforthestructureisC30H28O8 andthestructure
has a molecular weight of 516.53852g/mol.
Commercially available Rottlerin has a purity of 85 to
99%,dependingonthecompanies(Sigma,Calbiochem,Bio-
mol, etc.). Rottlerin is supplied as an orange-brown powder,
soluble in DMSO, chloroform, or ethanol, insoluble in water.
Rottlerin is not an approved drug although it shows a low
toxicity proﬁle in an animal model of Parkinson (mice) [9].
In this study, both intraperitoneal (3–7mg/Kg) and oral
(20mg/Kg) administration, exhibited protective eﬀects and
wasnottoxic.Inaddition,HPLCmeasurementsrevealedthat
the drug reached the target tissues in an intact and active
form (1125pg/mg brain tissue).
3. Rottlerin Usage:
TheOpenDebateonSelectivity
The commercial production of Rottlerin, for in vitro uses
only, began in 1994, following the paper by Gschwendt et al.
reporting that PKCδ is selectively inhibited by 3–6μM Rottl-
erin 5–30-fold stronger than other PKCs at the same concen-
trations [10].
Since then, many studies of PKCδ signaling have used
Rottlerin as a speciﬁc inhibitor and much of what is known
regarding the involvement of PKCδ in a variety of biological
processes derived from such studies.
However, most of these studies should be interpreted
with skepticism because shortly thereafter, it was demon-
stratedthatRottlerinhasnodirecteﬀectonPKCδ kinaseact-
ivity in vitro [11]. In addition, Rottlerin was found to inhibit
many other protein kinases, such as PRAK, MAPKAP-2, Akt/
PKB, and CaMK [12].
Moreover, in an illuminating study, Soltoﬀ demonstrated
thatRottlerinuncouplesmitochondrialrespirationfromoxi-
dative phosphorylation thereby reducing ATP levels and af-
fecting several cellular functions [13]. The author concluded
that“theconceptthatRottlerinisaspeciﬁcinhibitorofPKCδ
should be challenged and changed within the entire scientiﬁc
community. It appears to be entirely without merit to con-
tinue to conclude reﬂexively that its mechanism of action is
due to its direct inhibition of PKCδ activity.”
Onthebasisofthesecriticalaspectsabouttheapplication
of Rottlerin as a PKCδ inhibitor, LC Laboratories discontin-
ued selling Rottlerin.
Soltoﬀ’s study provided an instructive insight into the
ability of Rottlerin to modulate several biological and bio-
chemicalprocessesinaPKCδ-independentway.Forinstance,
in pancreatic acinar cells, 6μM Rottlerin (Calbiochem) de-
pletes ATP levels, thus preventing the phosphorylation of
many signaling proteins and inhibiting enzymatic secretion
and several intracellular pathways, in a PKCδ-independent
manner. Consistently, the studied inhibitory eﬀects of Rot-
tlerin, in pancreatic acini were mimicked by the mitochon-
drial uncouplers CCCP and FCCP [14].
Nonetheless, many studies of PKCδ signaling have used
Rottlerininconjunctionwithothermethods,suchasoverex-
pression of constitutively activated PKCδ or downregulation
by dominant-negative PKCδ and PKCδ-small interfering
RNA, obtaining consistent and convincing results.
In order to resolve the question of whether Rottlerin is a
PKCδ inhibitor, Soltoﬀ suggested that, although Rottlerin is
not eﬀective in inhibiting PKCδ activity in vitro, the reduc-
tion of ATP levels can block PKCδ tyrosine phosphorylation
and indirectly inhibit its translocation and kinase activity in
cultured cells [15].
Alternatively, it is possible that Rottlerin, although not
directly on PKCδ, can produce cellular changes that mimic
those produced by the direct inhibition of PKCδ. In this
regard, an emblematic example of convergent but indepen-
dent eﬀects of Rottlerin and PKCδ downregulation is the
recent study by Matta et al. [16] performed in chicken chon-
drogenic mesenchymal cells. The authors found that both
PKCδ silencing and 2.5–10μM Rottlerin (Sigma) decreased
the protein levels of Sox9, the major cartilage-speciﬁc trans-
cription factor, and impaired cartilage matrix production.
However, they concluded that the inhibition of cartilage for-
mation in the Rottlerin-treated cells is probably PKCδ in-
dependentfortwomainreasons:(i)theyfailedtounambigu-
ously demonstrate inhibition of PKCδ activity by Rottlerin
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the phosphorylation status of ERK1/2, one of the key regu-
lators that inﬂuence in vitro chondrogenesis.
It is quite surprising that, despite the warning about the
lack of speciﬁcity and activity towards PKCδ, Rottlerin is still
used as a selective PKCδ inhibitor. A recent patent has even
claimed the usage of Rottlerin synthetic analogs, as PKCδ in-
hibitors, in the treatment of Parkinson’s disease (patent ap-
plication number: 20110112182).
Therefore, it cannot be stated with certainty that Rott-
lerin is not a PKCδ inhibitor; rather, the current challenge
should be to discern between PKCδ-dependent and PKCδ-
independent Rottlerin eﬀects.
With the aim to explain and reconcile the conﬂicting
ﬁndings from the literature, we propose an additional indi-
rect mechanism by which Rottlerin can inhibit or promote
certain PKCδ functions, depending on PKCδ cellular redis-
tribution. Since PKCδ activation has been classically associ-
ated with transient translocation to the plasma membrane,
theRottlerinpreventionofPKCδ membranerecruitmenthas
beeninterpretedinsomestudiesasaproofofdirectRottlerin
inhibition.
However, we noticed that the Rottlerin inhibition of ago-
nist-induced translocation of PKCδ has been documented in
cells expressing functional caspase 3, such as neutrophils,
where treatment with 10μM of Rottlerin for 15min prior to
PMA stimulation reduced the membrane localization of
PKCδ [17], in human monocytes [18], in human promono-
cytic U937 cells [19], and in pancreatic acinar cells, where
pretreatment for 2h with 6μM Rottlerin inhibited by more
than 60% the CCK-8-stimulated PKCδ translocation to par-
ticulate fractions [14].
Often, apoptosis induced by Rottlerin has been ascribed
to the (apparent) PKCδ inhibition and interpreted as a pro-
tective role of PKCδ against cell death. For example, PKCδ
was reported to act as a prosurvival factor in the MCF-7 hu-
man breast cancer cell line since inhibition of PKCδ by 1.5–
9.0μM Rottlerin (Sigma) decreased survival in response to
radiation-induced DNA damage [20]. Further, PKCδ has
been described as antiapoptotic because its inhibition by
Rottlerin promotes apoptotic death [21, 22].
However, the claimed antiapoptotic role of PKCδ,
although cannot be excluded, has been likely confused with
aP K C δ-independent apoptotic eﬀect of Rottlerin; in fact, we
should take into account that PKCδ is a caspase 3 substrate
and several studies suggested that proapoptotic function of
PKCδ is associated with its cleavage by caspase 3 in the hinge
region, rendering the catalytic fragment (δCF) constitutively
active, thereby eliminating the membrane translocation re-
quirement [23–25].
It is worth highlighting that, although the δCF localizes
to the nucleus and triggers apoptosis, its dependence on cas-
pase 3 indicates that it cannot be the trigger of apoptosis
per se, but it may function to amplify an apoptotic stimulus.
Moreover, some reports indicate that PKCδ may also posi-
tivelyfeedbackoncaspase3activation,thusinducingfurther
apoptosis, at least in dopaminergic neurons [26].
Therefore, the hypothesized sequence of events could be
as follows: Rottlerin induces apoptosis via caspase 3 acti-
vation (see below), which in turn, cleaves PKCδ,t h u sp r e -
venting PKCδ membrane translocation and inducing δCF
nuclear localization, with enforced apoptotic eﬀect.
In this scenario, the inhibitory eﬀect of Rottlerin on full-
length PKCδ translocation and activity could be fully con-
ceptually recovered (in caspase 3 expressing cells), but com-
pletely revised as far as the molecular mechanism is con-
cerned.
Nevertheless, some exception to the rule seems to exist.
For example, Zhang et al. reported that 15μM Rottlerin
(Calbiochem) prohibits PKCδ translocation from cytosol to
membraneandsuppressesPKCδ kinaseactivityincaspase-3-
deﬁcient MCF-7 cells [27]. Although this ﬁnding apparently
confutesourhypothesis,itisinconﬂictwithapreviouspaper
reporting the absence of PKCδ cleaved forms in MCF-7 cells
after tumor necrosis factor-α (TNF-α)t r e a t m e n t[ 28].
In a further eﬀort to reconcile divergent data, since the
Zhang group did not measure caspase 3, it could be hypothe-
sized that in their MCF-7 cell line, caspase 3 was not com-
pletely downregulated.
4. Rottlerin andCancer
Rottlerin exhibits a number of therapeutic eﬀects against a
variety of cancer cells. Because of the diﬀerences in Rottle-
rin outcomes, cellular models, experimental strategies, and
exploited pathways, the current status of the Rottlerin anti-
cancer potential against various cancers is analyzed below
under diﬀerent headings.
5.Rottlerin andApoptosis
Apoptosis is a particularly desirable type of cancer cell death
because it causes no inﬂammation and can result in the dis-
sipationofthetumorwithnodamagetosurroundingtissues.
Apoptosis can be triggered by diﬀerent stimuli and
two major pathways of cell death have been identiﬁed: the
intrinsic (mitochondrial or type II) and the extrinsic (re-
ceptor-mediated or type I) pathway.
The intrinsic pathway is regulated by BCL2 family mem-
bers. These proteins have been characterized into three main
groups that diﬀer in how they regulate apoptosis: the anti-
apoptotic or survival proteins, such as BCL2 and BCLXL, the
proapoptoticdeathsignalingproteins,suchasBAXandBAK,
and the regulatory proteins, the so-called BH3-only proteins,
such as BAD, BID, and BIM, which are essential for initiation
of apoptosis [29]. The eﬀector function of apoptotic mem-
bers is mediated through release of proteins from the mito-
chondrial intermembrane space, such as cytochrome c,
through the process of mitochondrial outer membrane per-
meabilization (MOMP). Cytochrome c binds apoptotic pep-
tidase activating factor- (APAF-) 1 resulting in the activation
of caspase 9, which in turn, activates caspase 3. Caspase
3 mediates cleavage of vital cellular proteins, including the
nuclear enzyme poly(ADP-ribose) polymerase (PARP) [30].
The extrinsic pathway occurs independently of the BCL2
family and is triggered by ligation of death receptors
belonging to the TNF family. Binding of speciﬁc ligands
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of Fas-associated death domain (FADD) adapter protein,
formation of the death-induced signaling complex (DISC),
recruitment of the initiator caspases 8 and 10, and subse-
quently activation of the eﬀe c t o rc a s p a s e s3 ,6 ,a n d7[ 31].
Several early reports have shown that Rottlerin can in-
duce apoptosis in cancer cells, such as in lung cancer, breast
cancer, chronic lymphocytic leukemia, and multiple myelo-
ma cells [20, 32–34].
However, most of these studies ascribed the Rottlerin
apoptotic actiontoPKCδ inhibition; hence,as discussed pre-
viously, many of them likely should be reread in the light of
the current views regarding Rottlerin’s mode of action.
Obviously, the existence of PKCδ-unrelated Rottlerin
outcomes does not reﬂexively imply that PKCδ is not in-
volvedinthecontrolofapoptosis.Infact,althoughtheinitial
results on the role of PKCδ in apoptotic signaling pathways
wereverycontradictory[21,22],recentstudiessupportarole
for PKCδ in apoptosis inhibition, at least in breast cancer
cells. For example, it has been demonstrated that PKCδ
downregulation by small interfering RNA (siRNA) transfec-
tion, per se induces apoptosis in MDA-MB-231 breast cancer
cells [35].
Mechanistically, the authors found that PKCδ silencing
led to an increase in MEK1/2 and ERK1/2 phosphorylation,
indicating that PKCδ conceivably exerts its survival support
by suppressing the Ras/MEK/ERK pathway [35].
Moreover, the existence of alternatively spliced variants
of PKCδ with distinct functions in the apoptotic cascade
has been recently discovered and could represent the switch
that determines cell survival or cell death. The splice variants
described so far include caspase 3 resistant full-length PKCδ
protein and a truncated protein containing the regulatory
domain, but not the catalytic one, which localizes to the
plasma membrane and likely acts as an endogenous domi-
nant negative inhibitor [36].
In recent publications, the anticancer potential of Rottle-
rinhasbeenconﬁrmedindiﬀerentcancercellsandmarkedly
diﬀerent mechanisms of action have been described, again
with enigmatic results as far the PKCδ involvement is con-
cerned.
For instance, Zhang et al. reported that Rottlerin sensi-
tizesMCF-7breastcancercellstoTRIAL-mediatedapoptosis
by PKCδ-dependent inhibition of the transcription factor
nuclear factor κB( N F κB), a major regulator of apoptosis
[27].
However, we have recently reported that NFκB is a direct
RottlerintargetinMCF-7cellsand,althoughtheexactmech-
anism of inhibition is not deﬁned yet, it occurs in a PKC(δ)-
independent manner [37]. Furthermore, although there is
evidence that PKCδ, or its downstream eﬀector PKD1, can
activateNFκB[38,39],wehaverecentlyfoundthatthePKCδ
isoform of novel PKCs is only marginally involved in PKD1
activation in MCF-7 cells [40]. Therefore, as already noted
for PKCδ membrane translocation, the Zhang’s MCF-7 cell
line strongly diﬀers from the MCF-7 cells used in our and
other studies.
Accumulating evidence suggests that Rottlerin plays a
PKCδ-independent role in modulating apoptotic cell death
signaling. For example, in colon carcinoma, 1–10μM Rott-
lerin (Calbiochem) sensitizes cancer cells to tumor necrosis
factor-related apoptosis-inducing ligand- (TRAIL-) induced
apoptosis via uncoupling of the mitochondria independent
of PKC [41].
Further, PKCδ-independent and mitochondrial un-
coupling-mediated apoptotic death has been also described
in HT1080 human ﬁbrosarcoma cells, where 0.5–10μMR o t -
tlerin caused AIF translocation, with no involvement of cas-
pases 3 and 9 [42].
Therefore, the mitochondrial membrane depolarization
by Rottlerin cannot only aﬀect phosphorylation and activity
of proteins by reducing ATP levels, but can also account for
PKCδ-unrelated apoptotic events.
Ontheotherhand,italsoappearsthattheintrinsicapop-
totic pathway is not the only weapon that Rottlerin has to kill
cancer cells. In fact, in a panel of human malignant tumor
cells (HCT116, HT29, LNCap, PC-3, Hep3B, U2OS, SaOS2,
andCakicells),Limetal.[43,44]haverecentlyreconstructed
ac o m p l e t e l yd i ﬀerent Rottlerin-triggered chain of events
leading to apoptotic death. They found that 1–10μM Rottle-
rin (Biomol) treatment resulted in death receptor 5 (DR5)
upregulation, mediated by the transcription factor CHOP/
GADD153. The increase in DR5 protein, a member of the
TNFreceptorfamily,wasabletotriggerapoptosiseveninthe
absence of ligand, in a PKCδ-, p53-, and ROS-independent
manner, and, at the same time, rendered cancer cells more
sensitive to the cytotoxic activity of TRAIL.
Since CHOP/GADD153 is induced by endoplasmic reti-
culum (ER) stress [45], the novelty of this study lies in the
fact that it demonstrates that Rottlerin can induce cell death
through a mechanism involving ER stress and the extrinsic
apoptotic pathway, alternatively or in addition to the mito-
chondria targeting and the intrinsic apoptotic cascade.
Importantly for possible Rottlerin application in cancer
treatment, Lim’s group found that Rottlerin stimulated apo-
ptosis preferentially in cancer cells, since no signiﬁcant apo-
ptotic eﬀect was observed in normal ﬁbroblasts and mesan-
gial cells.
The observation that normal and cancer cells display dif-
ferent sensitivity to Rottlerin has been recently conﬁrmed in
normal pancreatic acinar cells and pancreatic adenocarci-
noma MIA PaCa-2 cell line [46]. In this study the authors
found that 2–10μM Rottlerin (Sigma) dose dependently in-
duced cytochrome C release, mitochondrial membrane de-
polarization and stimulated not only apoptotic but also nec-
rotic death of PaCa cells. All these events were both PKCδ-
and Akt-independent and mediated by the Rottlerin inter-
ference in the prosurvival protein Bcl-xL, and Bim and Puma
complexes formation.
In this interesting study, PaCa cells were also subcutan-
eouslyinjectedintonudemice.Piecesofthetumorwerethen
transplanted into the tail of the pancreas of recipient nude
mice and animals were treated daily with intraperitoneal
injections of Rottlerin (0.5mg/kg) for 4 weeks. The in vivo
treatment resulted in inhibited tumor development and
increased apoptosis. Importantly, there was no diﬀerence in
body weight throughout the study period between control
and treated groups and extratumoral tissues, for example,
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Furthermore, Rottlerin did not activate caspase 8 in cul-
tured pancreatic cancer cells, indicating that it stimulates
only mitochondrial pathways of apoptosis. The initiator cas-
pase 8, indeed, is a key mediator of the type I apoptotic cas-
cade triggered by the ligand-bound Fas or TRAIL death re-
ceptors (DR4 and DR5).
Although the mechanisms underlying these diﬀerent
apoptotic responses remain to be determined, the ﬁndings
above suggest that the Rottlerin apoptotic eﬀect is general-
ized in cancer cells and can be achieved through multiple
pathways, likely cell-dependent.
Moreover, the intrinsic and the extrinsic apoptotic path-
ways rarely overlap upstream of caspase 3 but they are not
mutually exclusive and some crosstalk has been described.
For example, caspase 8, the initiator of the extrinsic pathway,
mediates the activation of BID, a regulatory, proapoptotic
member of the BCL2 family. Once BID is cleaved by caspase
8, truncated-BID translocates from the cytosol to mitochon-
dria, where it can mediate cytochrome c release thereby bri-
dging type I and II apoptosis [47].
6. Rottlerin in Combination withOther
Anticancer Drugs
Combination therapy refers to the use of drugs that target
diﬀerent signal transduction pathways, resulting in additive
orsynergisticeﬀects,therebyallowingareductionofthedose
of the most toxic component and sometimes overcoming the
cellular resistance mechanisms.
Rottlerin has been described to potentiate the cytotoxic-
ity towards tumor cells of diﬀerent chemotherapeutic agents.
In addition to the already mentioned Tillman’s study
[41],otherinvestigatorshavetestedRottlerinincombination
with TRAIL. Kim et al. [48] found that glioma cells, refrac-
tory to traditional radio and chemotherapy due to overex-
pression of inhibitors of apoptosis, such as survivin and X-
chromosome-linkedIAP(XIAP),aresensitizedtoTRAIL-in-
duced apoptosis by subtoxic doses of Rottlerin. Yet, in this
case the Rottlerin action was independent of PKCδ.
Rottlerin did not enhance cell death in astrocytes, further
conﬁrming that normal and cancer cells display diﬀerent
sensitivity to Rottlerin.
AnotherstudyreportedthatRottlerinmightprovidether-
apeutic eﬀects in malignant glioma cells when used in com-
bination with other chemotherapeutics. For example, coad-
ministrationof01–25μMRottlerin(Calbiochem)withSora-
fenib, an inhibitor of Raf kinase and other tyrosine kinases
that target the Raf/Mek/Erk pathway, elicited an additive
growth inhibitory eﬀect and enhanced apoptosis in a panel
of human malignant glioma cells [49].
Although, once again, the authors ascribed the Rottlerin
eﬀects to PKCδ inhibition, the combination of Rottlerin and
sorafenibwasconﬁrmedtohavenosigniﬁcantadditiveeﬀect
on human nonneoplastic cell lines.
Rottlerin has also been used in coadministration with
imatinib, the BCR/ABL tyrosine kinase inhibitor eﬀective for
treatment of chronic myeloid leukemia. Kurosu et al. [50]
found that 1μM Rottlerin (Calbiochem), independently of
PKCδ, synergized with imatinib to induce apoptosis in leuk-
emic cells, without aﬀecting BCR/ABL. Since mitochondrial
uncouplers, other than Rottlerin, also induced apoptosis of
BCR/ABL-expressing cells in a synergistic manner with ima-
tinib, the authors concluded that Rottlerin enhances ima-
tinib-induced apoptosis through its mitochondrial uncoupl-
ing eﬀect.
Although this experimentation is at its very beginning,
the ﬁndings presented so far suggest that Rottlerin, as an
adjuvant to chemotherapy, can enhance chemosensitivity of
cancer cells and could alleviate chemotherapy-associated
toxic eﬀects.
7. Rottlerin and Autophagy
Autophagy is an evolutionarily conserved, multistep process
thatischaracterizedbythevesicularsequestrationanddegra-
dationoflong-livedcytoplasmicproteinsandorganelles.The
resulting double-membrane vesicle, termed autophagosome,
is under the control of a highly organized and hierarchical
team of autophagy-related genes (ATG) proteins. The auto-
phagosome ultimately fuses with a lysosome and the auto-
phagic cargo is degraded by the action of acid-dependent en-
zymes [51].
Autophagy (microautophagy) can promote cell survival
during stresses such as starvation and hypoxia, both provid-
ing a means of recycling macromolecules as an alternative
energysourceandeliminatingtoxicdebrisbut,whenthecell-
ular stress is continuous or excessive, cell death may ensue
(macroautophagy or type II programmed cell death). Then
the question is perhaps quantitative: microautophagy is pro-
tective but macro-autophagy kills cells.
Because the frequent deregulation of the apoptotic path-
way in cancer cells constitutes an important clinical problem
in radiotherapy and chemotherapy, as an alternative route of
cell death, (macro)autophagy is currently considered an im-
portant research target for new anticancer drugs.
Although Rottlerin-promoted cell death has been mainly
ascribed to apoptosis, a sign of autophagy induction was
ﬁrstly described about fourteen years ago in apoptosis-resis-
tantratandhumangliomas[52].Inthatstudy,5–20μMRot-
tlerin treatment resulted in growth arrest, packaging of cel-
lular components within membranes, and accumulation of
cytoplasmic vacuoles.
Since then, other studies described Rottlerin as an induc-
torofautophagy,againthrough (apparently)diﬀerent mech-
anisms.
In HT1080 ﬁbrosarcoma cells, which, however, die by
apoptosis, an early response to Rottlerin is the induction of
autophagy by a PKCδ-independent mechanism, likely medi-
ated by the mitochondrial membrane depolarization [42].
TheOzpolatandAkar’sgroupreportedthat2–4μMR ot-
tlerin induced autophagy through inhibition of PKCδ/trans-
glutaminase 2 (TG2) in a panel of pancreatic cancer cells that
are known to be resistant to most chemotherapeutic agents
[53, 54]. In these studies, Rottlerin- or TG2 siRNA-treated
cells clearly showed formation of autophagic vesicles and a
signiﬁcant accumulation of endogenous microtubule-asso-
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autophagy. Since knockdown of PKCδ expression by a speci-
ﬁc siRNA led to the downregulation of TG2 protein, the au-
thors concluded that PKCδ regulates TG2 expression and
Rottlerin induces autophagy through PKCδ inhibition. As a
direct proof, they showed that Rottlerin caused down-regu-
lationofPKCδ,protein,andmessenger,withnoapoptosis,as
judged by the lack of PARP cleavage and Annexin V posi-
tivity.
Although the role of TG2 in the control of autophagy has
been also reported by other groups [55] ,t h e r ea r es o m eo r i -
ginal aspects in this study that merit to be further discussed.
First, to our knowledge, there is only another study re-
porting that Rottlerin causes downregulation of PKCδ.
Brownetal.[56]foundreductionsinthelevelsofPKCδ RNA
and full-length protein both in vivo (Rottlerin-treated mice)
and in cultured macrophages.
Because Rottlerin has been thought to only inhibit PKCδ
translocation and kinase activity, these unusual ﬁndings
could help explain some of the controversy that has arisen
concerning the Rottlerin modulation of PKCδ and should be
further exploited.
The second interesting aspect of this study is the ﬁnding
that Rottlerin through the PKCδ/TG2 axis regulates down-
stream targets, such as NFκB and Bcl-2. In fact, among the
diverse roles, TG2 is known to activate NFκB[ 57] and hence
itstargetgeneproductBcl-2,which,inadditiontoprotecting
against apoptosis, can also prevent cells from undergoing
autophagybybindingandinhibitingtheautophagy-promot-
ing protein Beclin-1.
It is of interest to recall that the inhibition of NFκBb y
5–20μM Rottlerin (Calbiochem) has been documented by
our group in several other cell types [58, 59], MCF-7 cells
included [37]. However, in MCF-7 cells, the PKCδ/TG2 axis
cannot be operative since these cells are TG2 deﬁcient [60],
inmarkedcontrastwiththemajorityofpancreaticcancercell
lines, which overexpress TG2.
This therefore can be considered as an example of how
Rottlerin, though targeting diﬀerent signaling molecules in
diﬀerent cells, can converge the response on a common
eﬀect.
Interestingly, the Ozpolat and Akar’s group reported that
Rottlerin, through the PKCδ/TG2 axis also downregulated
phosphorylated mammalian target of rapamycin (mTOR), a
major negative regulator of autophagy [61].
The mTOR serine/threonine kinase is the catalytic com-
ponent of two distinct protein complexes, mTORC1 and
mTORC2. mTORC1 consists of a complex that includes
mTOR and a protein known as RAPTOR (regulatory asso-
ciated protein of mTOR) whereas mTORC2 consists of
a complex that includes mTOR and a protein known as
RICTOR (rapamycin-insensitive companion of mTOR).
Only mTORC1 is allosterically inhibited by rapamycin and
negatively regulated by the tuberous sclerosis complex
(TSC)1/TSC2, also called Hamartin/Tuberin, tumor sup-
pressor heterodimer.
The mTOR is an important regulator of multiple cellular
functions besides autophagy, including proliferation, diﬀer-
entiation, tumorigenesis, and apoptosis. Increasing evidence
suggests that mTOR is dysregulated in tumors [62]a n d
agents,otherthanRottlerin,whichtargetthemTORpathway
are in various stages of clinical development [63].
However, the Ozpolat and Akar’s group concluded that
Rottlerin-induced autophagy is not mediated by mTOR be-
causeRapamycinfailedtoinduceautophagyinMDA-Panc28
cells.
Since it is now recognized that the rapamycin eﬃcacy is
limited to few cancers [64], this is probably a peculiar feature
of pancreatic cancer cells.
Although the Ozpolat and Akar’s conclusion that auto-
phagy induction by Rottlerin is mTOR-independent may
seem limitative in the context of this review, a recent study,
performed in MCF-7 cells stably expressing enhanced green
ﬂuorescent protein- (EGFP-) LC3, has shown that Rottlerin
does promote autophagy through inhibition of mTORC1
[65].
The authors found that 3μM Rottlerin (Sigma) treat-
ment decreased phosphorylation of the mTORC1 substrates
40S ribosomal protein S6 kinase (p70S6K) and eukaryotic
translation initiation factor 4E-binding protein 1 (4E-BP),
only in TSC2 expressing cells, implying that mTORC1 inhi-
bition is mediated by TSC2 activation and TSC2 upstream
signaling.
SinceAMPKphosphorylatesandactivatesTSC2toswitch
oﬀ mTORC1 signaling, this study opened new mechanistic
perspectives in the usage of Rottlerin in cancer as an auto-
phagy inductor, as discussed below.
8. Rottlerin: Lookingbeyond
theMitochondrialUncoupling
There is general consensus that a major regulatory pathway
of mTOR is the activation of AMPK, which can inhibit
mTOR signaling by both direct and indirect mechanisms.
AMPK, indeed, increases the inhibitory activity of the TSC1-
TSC2 complex toward mTOR, by phosphorylating TSC2
at speciﬁc sites (Thr-1227 and Ser-1345) [66]. In addition,
AMPK directly phosphorylates mTOR at Thr-2446, inhibit-
ing its activity [67] and also directly phosphorylates the
mTOR binding partner RAPTOR on Ser722 and Ser792,
causing 14-3-3 binding to raptor and inhibition of
mTOR(C1) [68].
Since AMPK has a triple inhibitory eﬀect on mTORC1,
that is, direct inhibition of mTOR and raptor and enhance-
ment of the inhibitory action of the TSC complex, AMPK
activation inevitably leads to mTOR-dependent autophagy.
AMPK is an energy sensor that promotes energy produc-
tion and limits energy utilization to ensure cellular survival.
Infact,AMPKisactivatedunderconditionsthatdepletecell-
ularATPandelevateAMPlevels,suchasglucosedeprivation,
hypoxia, and mitochondrial uncouplers [69, 70].
AMP regulates AMPK by binding to the AMPK-γ sub-
unit and inducing a conformational change that exposes the
enzyme to upstream kinases, which activate AMPK by phos-
phorylation of Thr172 [71]. Moreover, AMP confers to
AMPKresistanceforinactivatingphosphatases.Atleastthree
diﬀerent upstream AMPK kinases have been recognized, the
major one is the ubiquitously expressed LKB1 tumor sup-
pressor [72].The Scientiﬁc World Journal 7
Consistent with its uncoupling activity and reduction of
cellular ATP levels, 2–10μM Rottlerin (Calbiochem) has
been reported to activate AMPK in vascular cells and tissues,
through a still undeﬁned mechanism possibly involving
LKB1 [73].
Unfortunately, there are not published studies on AMPK
activation by Rottlerin in cancer cells.
However,althoughcancersaregenerallymoredependent
on glucose metabolism rather than mitochondrial respira-
tion for energy requirements, we should consider that the
AMP/AMPK axis is very sensitive and even minimal changes
in the intracellular ATP/ADP ratio ensures that AMPK is act-
ivated, thanks to the activity of adenylate kinase, which cata-
lyzes the reaction 2 ADP → ATP + AMP.
Therefore, since the Rottlerin uncoupling eﬀects have
been documented in a discrete number of cancer cells, it is
tempting to speculate that AMPK activation is a widespread
Rottlerin outcome.
Intriguingly, AMPK activation by Rottlerin could also
account for NFκB inhibition and downregulation of NFκB
target genes. In fact, NFκB inhibition by AMPK has been de-
monstrated in HUVECs by both AMPK chemical activation
(AICAR)andoverexpressionofaconstitutivelyactiveAMPK
[74]. Although the precise mechanism was not investigated
in details by the authors, other researchers reported that
AMPK enhances the activity of SIRT-1, a NAD+-dependent
histone deacetylase, resulting in the deacetylation of several
transcription factors, including NFκB, which is deacetylated
at Ser 310 of the p65 subunit and inactivated [75].
Importantly, this last study has been performed in non-
small-cell lung cancer (NSCLC) cell lines.
9. Rottlerin andAMPK:
Other MechanisticPerspectives
As stated above, although not supported yet by experimental
evidence, it is reasonable to hypothesize that the well docu-
mented uncoupling property of Rottlerin promotes AMPK
activation in normal as well-as in cancer cells, regardless of
the type of metabolism upon which they rely for energy
production.
Among the several pathways and molecules under the
control of AMPK, the AMPK/p53/p21 and the AMPK/p27
axes are particularly relevant in cancer.
The p53 transcription factor is a tumor suppressor that
can be activated by cellular stress signals such as DNA dam-
age, ultraviolet light, and oncogenes. Under normal condi-
tions, p53 is rapidly degraded by ubiquitin-mediated prote-
olysis; however, posttranslational modiﬁcations such as pho-
sphorylationstabilizep53andenhanceitsDNAbindingacti-
vity towards promoter regions of target genes.
It has been demonstrated that both chemical activation
of AMPK [76] and expression of constitutively active AMPK
[77] result in phosphorylation of human p53 at Ser15, p53
stabilization, and enhanced transcriptional activity.
AMPKandp53arelinkedbyamutualactivationloop,by
which AMPK stabilizes p53, which, in turn, activates AMPK
through complex and incompletely deﬁned mechanisms,
which, however, clearly lead to inhibition of mTOR and in-
duction of autophagy [78, 79].
As far as the AMPK/p27 axis is concerned, recent studies
reported that activated AMPK phosphorylates the cell cycle
inhibitor p27 at Thr 198, thus stabilizing p27 and prolonging
its activity [80].
AMPK can also induce the transcription of the p27 gene
by a mechanism involving in sequence AMPK/SIRT-1/FOXO
pathway. As mentioned above, AMPK enhances the activity
of SIRT-1, resulting in the deacetylation of several transcrip-
tion factors, Forkhead box class O (FOXO) included. How-
ever, FOXO deacetylation by SIRT-1 enhances its transcrip-
tional activity, resulting in increased expression of p27 [81]
and induction of autophagic ﬂux [82].
Notably, in addition to inhibiting the cell cycle progres-
sion and to protecting against apoptosis, p27 has also been
implicated in the induction of autophagic death [83].
10. AntimetastaticEffects of Rottlerin
Migration and adhesion of tumor cells are the most impor-
tant prerequisites for the formation of metastasis. Metastatic
process involves the separation of cancer cells from the pri-
mary tumor, migration into the extracellular matrix, blood
vessel invasion, adhesion to endothelium, and extravasation
and growth in a secondary organ.
Celladhesion,thebinding ofacelltoextracellularmatrix
or another cell, involves cell adhesion molecules such as cad-
herins and integrins.
Cadherins are Ca2+-dependent type-1 transmembrane
proteins that participate in the maintenance of proper cell-
cell contacts. E-cadherin is the major adhesion molecule of
epithelial cells. E-cadherin is considered a tumor suppressor
protein, preventing cancer cells from detaching from a
primarytumormass,travelingthroughthebloodstream,and
invading other tissues [84].
Integrins are a large family of heterodimeric transmem-
brane glycoproteins, composed of noncovalently linked α
and β subunits that mediate mainly cell-matrix interactions.
In addition, integrins have been considered as signaling re-
ceptors essential for proper cell growth and motility [85].
Alterations in integrins composition have been correlated
with malignant progression and tumor invasion in vivo and
in vitro [86].
Cell migration in metastasis involves turnover of focal
adhesion complexes, which link the intracellular cytoskele-
tonandthetransmembraneintegrins,which,inturn,anchor
cells to the extracellular matrix and relay signals therein.
Focal adhesion complex consists of several component
proteins, including focal adhesion kinase (FAK), vinculin,
andpaxillin.Amongthese,FAKanditsactivatedform,phos-
phoFAK(Tyr397),playscrucialrolesinmediatingtheassem-
bly and disassembly of the complex. Once activated by clus-
tering of integrins, pFAK activates downstream GTPases
RhoA and Rac-1, leading to polymerization of actin and for-
mation of stress ﬁbers [87].
Rottlerin has been demonstrated to aﬀect cell motility
and adhesion by modulating the expression of a number of8 The Scientiﬁc World Journal
cellular adhesion molecules involved in the metastasis pro-
cess.
Again, most studies ascribe the Rottlerin eﬀects to direct
inhibition of PKCδ.
The only study reporting a PKCδ-independent antimeta-
staticpotentialof10μMRottlerin(Biomol)hasbeenrecently
publishedby Linet al.[88], whodemonstrated that Rottlerin
reduced cell motility and cell adhesion to substratum matrix
of follicular thyroid carcinoma cells. Moreover, Rottlerin
treatment decreased protein levels of integrin β1, FAK, and
paxillin with consequent disassembly of the focal adhesions.
Rottlerin also reduced expression level and activity of Rac-1
and Rho GTPases, which was accompanied by disrupted
actin stress ﬁber formation.
Verysimilarresultshadbeenpreviouslyobtainedinrenal
carcinoma, prostate cancer, and colon carcinoma cells,
although ascribed to PKCδ inhibition [89–91].
Cell motility is just a component of the invasion process.
Invasion of the surrounding tissue by tumor cells also in-
volves degradation and remodeling of extracellular matrix.
These processes are mediated by two types of proteolytic en-
zymes: the plasminogen activator system components and
the matrix metalloproteinases (MMPs).
In recent works, again through PKCδ inhibition, 2.5–
10μM Rottlerin treatment decreased MMP-12 levels and in-
vasiveness of tenascin-stimulated glioma cells [92]a n dc a u s -
edamarkeddecreaseinPMA-inducedMMP-9secretionand
invasiveness in MCF-7 human breast cancer cells [93].
Similarly, 5μM Rottlerin (Calbiochem) had been previ-
ously found to markedly inhibit both FGF2- and TPA-in-
duced MMP-9 secretion in MCF-7 cells as well as basal and
PMA-induced MMP-9 expression in pituitary adenoma cells
[94, 95].
Although the mechanisms underlying the Rottlerin anti-
invasion properties are relatively poorly understood at pre-
sent, as many prometastatic genes are regulated by NFκB
(MMP-9 and E-Cadherins, among others), it is reasonable to
proposethatthesuppressiveeﬀectofRottlerinonNFκBacti-
vation, rather than (or in addition to ?) PKCδ inhibition, is
determinant in the blockage of metastatic cell functions.
11. Conclusion
This review, focused on the work performed so far on Rot-
tlerinanticancerproperties,demonstratesthatRottlerindoes
not function by virtue of interacting with a single well-deﬁn-
ed molecular target, but supports the concept that it acts
upon numerous biochemical and molecular mechanisms.
There is also the remote possibility that the pleiotropic
Rottlerin eﬀects could be due to impurities present in the
commercial preparations. However, as speciﬁed throughout
thisreview,thediﬀerenteﬀectsdescribedhavebeenobserved
by using commercial Rottlerin from diﬀerent companies, at
d o s e sr a n g i n gf r o m1t o2 5μM. Moreover, we veriﬁed that
the commercial preparation from Calbiochem is 100% pure,
as evidenced by the single peak in the capillary zone electro-
phoresis electropherogram (unpublished data).
Another complicating factor is the debated activity of
Rottlerin towards PKCδ, an old question that is still far from
being clariﬁed.
Therefore, it is extremely diﬃcult, if not impossible, to
formulateanunifying hypothesis. This isdue,notonlytothe
diﬀerentmechanisms ofactiondescribed aswellastothecell
speciﬁcity, but also to the existence of possible crosstalks and
common eﬀectors among the diﬀerent cell death pathways.
Whilethereisstillmuchtolearnaboutthemolecularmecha-
nisms underlying the multiple Rottlerin anticancer eﬀects, it
is also true that the ability to attack multiple targets are in
favor of Rottlerin being developed as a drug for prevention
and therapy of various cancers. In the last years indeed, the
tendency to adopt a multitarget-based anticancer therapy is
becoming imperative to decrease the probability that cancer
cells will develop chemoresistance.
Although the Rottlerin potency in vivo remains almost
unknown, its prospects are greatly anticipated. It might
thereforebeexpectedthattheRottlerindiversiﬁedanticancer
eﬀects that have been already shown in a variety of tumor
cell types, will soon provide strong preclinical data for the
justiﬁcation of clinical studies in humans as a metastatic can-
cer preventive/curing approach.
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